Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
The FDA today approved a new 200 unit/mL formulation of Eli Lilly and Company’s pre-filled pen containing insulin lispro (Humalog U-200 KwikPen) for the improvement of glycemic control in patients with type 1 and type 2 diabetes.
As the first concentrated mealtime insulin analog to receive FDA approval, the Humalog U-200 KwikPen delivers the same dose as Lilly’s Humalog U-100 KwikPen in half the volume. Compared with the 300 units of insulin held by the U-100 formulation, the U-200 KwikPen holds 600 units, allowing diabetics to change their pens less frequently.
http://www.pharmacytimes.com/news/New-Strength-of-Insulin-Pen-Gets-FDA-Nod
As the first concentrated mealtime insulin analog to receive FDA approval, the Humalog U-200 KwikPen delivers the same dose as Lilly’s Humalog U-100 KwikPen in half the volume. Compared with the 300 units of insulin held by the U-100 formulation, the U-200 KwikPen holds 600 units, allowing diabetics to change their pens less frequently.
http://www.pharmacytimes.com/news/New-Strength-of-Insulin-Pen-Gets-FDA-Nod